Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462590 | 0.83 | GLA (0.32) | AOC3ALDH1A1CYP2C9 | |
| SCHEMBL28417289 | 0.80 | CYP2C19 (0.36) | AOC3 | |
| SCHEMBL20462607 | 0.80 | AOC3 (0.33) | AOC3ALDH1A1CYP2C9 | |
| SCHEMBL20464251 | 0.77 | AOC3 (0.34) | AOC3ALDH1A1CYP2C9 | |
| SCHEMBL20462604 | 0.74 | AOC3 (0.33) | AOC3ALDH1A1CYP2C9 | |
| SCHEMBL20462589 | 0.74 | ALDH1A1 (0.34) | AOC3ALDH1A1CYP2C9 | |
| SCHEMBL20464220 | 0.72 | HTT (0.42) | AOC3ALDH1A1CYP2C9 | |
| SCHEMBL10512741 | 0.71 | — | — | |
| SCHEMBL14845683 | 0.69 | — | — | |
| SCHEMBL7771015 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20210395225-A1 | FUNCTIONALIZED AMINOTRIAZINES | LEADXPRO AG (CH) | 2021-12-23 | — | — | US | disclosed |
| WO-2020102098-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395225-A1 | FUNCTIONALIZED AMINOTRIAZINES | TBXA2R, ADORA2B, ADORA2A | AOC3 63/4885ALDH1A1 778/4885CYP2C9 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.